due to allergies, neurodiversity, sensory problems or coeliac disease) [98,99,102,112]
The lawsuit claims that the two companies, Novo Nordisk and Eli Lilly, knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis. Their failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate, it continues
If you suspect an adverse reaction to either medication, report it through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
Shoichet, B
However, the best drug is always the one that is right for your individual health profile, medical history, and goals not the one with the highest headline number